Pediatric rheumatology

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis

RMD OpenPublished Matched case-control study

An erratum to this article was published (RMD Open, Jun 2023 ↗)

Main finding · New-onset uveitis rate, MTX vs no MTX (adjusted)Result — go to the resultHazard ratio 0.35 95% CI 0.17–0.75

Authors' conclusion

This study demonstrates an independent protective effect of MTX on new-onset uveitis in patients with biological-naïve JIA.

Study context

Population
Patients with biological-naïve Juvenile Idiopathic Arthritis (JIA), University Medical Centre Utrecht, the Netherlands
Participants
92 patients
Comparison
Methotrexate (MTX) exposure in JIA-U cases vs JIA controls without JIA-U
  • JIA-Un = 46
  • Controlsn = 46reference
Outcome
New-onset uveitis (JIA-U onset) by MTX exposure
Methodological detailsmatched 1:1 on JIA diagnosis date, age at JIA diagnosis, JIA subtype, ANA status and disease duration, multivariable time-varying Cox regression, single-centre
  • Matched 1:1 on JIA diagnosis date, age at JIA diagnosis, JIA subtype, ANA status and disease duration
  • Multivariable time-varying Cox regression
  • Single-centre

Main finding

New-onset uveitis rate, MTX vs no MTX (adjusted)

Hazard ratio

0.35

95% CI 0.17–0.75

MTXvs No MTX
HR 0.35 (95% CI 0.17–0.75)

As reported in the abstract

Observational data: associations, not effects.

Further findings

MTX discontinuation — Of JIA-U cases who discontinued, developed uveitis within 1 year · JIA-U cases significantly more often discontinued MTX
50% · P = 0.03

MTX ever-use and exposure years

Both ever-use of MTX and exposure years were lower in JIA-U cases than in controls

MTX dose, low (<10 mg/m²/week) vs standard (≥10 mg/m²/week)

No different effect observed between low and standard MTX dose

Original publication

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis. RMD Open. Published 24 April 2023. doi:10.1136/rmdopen-2023-003010

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.